ASX:PXS Pharmaxis (PXS) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free PXS Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume721,139 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.41%Price TargetN/A Stock AnalysisStock Analysis Get Pharmaxis alerts: Email Address Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. About Pharmaxis Stock (ASX:PXS)Pharmaxis Ltd, a clinical stage drug development company, engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. It operates through Mannitol Respiratory Business and New Drug Development segments. The company provides Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test for the treatment of asthma. It's product pipeline comprises oral pan-Lysyl Oxidase Inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events such as accidents, surgery, and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases including kidney, pulmonary, liver, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. The company also offers Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.Read More Ad Stansberry ResearchUrgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.Find out for free here. PXS Stock News HeadlinesDecember 4, 2023 | proactiveinvestors.com.auSyntara bolsters financial position with R&D tax incentiveNovember 21, 2023 | finance.yahoo.comHere's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More CloselyMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).October 19, 2023 | proactiveinvestors.com.auFIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slowsOctober 3, 2023 | proactiveinvestors.com.auPharmaxis to focus on clinical-stage drug developmentOctober 3, 2023 | proactiveinvestors.com.auPharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol businessOctober 2, 2023 | marketwatch.comPharmaxis to Sell Mannitol Respiratory Business As Part of 'Major' RestructuringAugust 30, 2023 | proactiveinvestors.com.auFIVE at FIVE AU: ASX gains as inflation easesMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).July 13, 2023 | finance.yahoo.comPharmaxis says majority of patients in fibrosis trial see significant improvementJune 5, 2023 | finance.yahoo.comPXS.AX - Pharmaxis LtdMay 25, 2023 | proactiveinvestors.comPharmaxis extends scarring collaboration after encouraging resultsMay 24, 2023 | proactiveinvestors.comPharmaxis achieves 30% reduction in scar tissue with topical LOX inhibitor in Phase 1C study; extends UWA collaborationMay 21, 2023 | finance.yahoo.comPharmaxis Ltd (PXS.XA)April 11, 2023 | proactiveinvestors.com.auPharmaxis adds combination treatment arm to Phase 2 myelofibrosis studyApril 11, 2023 | proactiveinvestors.comPharmaxis to accelerate plans for myelofibrosis combination study after FDA talksMarch 23, 2023 | proactiveinvestors.comPharmaxis' PXS-5505 doubles response rate to standard therapy in blood cancer in preclinical studies; features in prestigious journalFebruary 12, 2023 | finance.yahoo.comPharmaxis Second Quarter 2023 Earnings: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)January 28, 2023 | nz.finance.yahoo.comPharmaxis Ltd (PXS.AX)January 15, 2023 | proactiveinvestors.comPharmaxis strengthens board with appointment of experienced healthcare analyst Hashan De Silva as non-executive directorJanuary 9, 2023 | proactiveinvestors.comPharmaxis secures almost A$5 million in research and development tax incentivesDecember 20, 2022 | proactiveinvestors.com.auPharmaxis' skin scarring study of its PXS-6302 asset now fully recruitedDecember 13, 2022 | proactiveinvestors.com.auPharmaxis appoints senior global pharma executive Dr Simon Green as a non-executive directorDecember 12, 2022 | proactiveinvestors.comPharmaxis cancer drug PXS-5505 profiled in two posters at American Society of Haematology ConferenceOctober 19, 2022 | proactiveinvestors.com.auPharmaxis receives interim data for Phase 2 cancer trialOctober 19, 2022 | proactiveinvestors.comPharmaxis welcomes positive interim data for Phase 2 cancer trialOctober 18, 2022 | msn.comLAST ORDERS: A light-hearted look at today’s market stuffSee More Headlines Receive PXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2019Today5/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:PXS CUSIPN/A CIKN/A Webwww.pharmaxis.com.au Phone+61-2-94547200FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.21Net Income$-18,430,000.00 Net Margins-154.92% Pretax MarginN/A Return on Equity-237.24% Return on Assets-48.68% Debt Debt-to-Equity Ratio367.85 Current Ratio1.81 Quick Ratio14.73 Sales & Book Value Annual Sales$11.89 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.32 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares722,610,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.64 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Gary Jonathan Phillips BPharm (Age 62)MBA, CEO, MD & Director Comp: $618.81kMr. David Morris McGarvey BA (Age 67)CA, CPA, CFO & Company Secretary Comp: $482.44kDr. Wolfgang G. Jarolimek B.Sc. Ph.D. (Age 59)Ph.D., Head of Drug Discovery Comp: $470.89kMs. Kristen Morgan B.Sc. (Age 51)BSc, MMedSc, PGDipBusAdmin, Head of Medical & Regulatory Affairs - Alliance Management Comp: $277.66kDr. Jana BaskarChief Medical OfficerMr. Cameron David Billingsley (Age 46)General Counsel More ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All CompetitorsInsidersGary PhillipsSold 2,771,000 sharesTotal: $83,130.00 ($0.03/share) PXS Stock Analysis - Frequently Asked Questions How were Pharmaxis' earnings last quarter? Pharmaxis Ltd (ASX:PXS) announced its earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share for the quarter. Pharmaxis had a negative net margin of 154.92% and a negative trailing twelve-month return on equity of 237.24%. What other stocks do shareholders of Pharmaxis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Ardent Leisure Group Limited Stapled Securities (AAD), Cineworld Group (CINE), General Electric (GE), International Consolidated Airlines Group (IAG), Lloyds Banking Group (LLOY), Myer (MYR), Qantas Airways (QAN) and Rolls-Royce Holdings plc (RR). This page (ASX:PXS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
